Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Norkrans

Showing results (151-160 of 162) with videos related to

Pageof 17
Sort By:
Journal of Viral Hepatitis|June 23, 2011
IL28B polymorphisms determine early viral kinetics and treatment outcome in patients receiving peginterferon/ribavirin for chronic hepatitis C genotype 1M Lindh, M Lagging, B Arnholm, et al.
European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology|November 25, 2011
Early quantification of HCV core antigen may help to determine the duration of therapy for chronic genotype 2 or 3 HCV infectionA Alsiö, A Jannesson, N Langeland, et al.
Ugeskrift for Laeger|May 30, 1994
[Controlled, clinical trial of isoprinosine administration to HIV-infected patients. Results of a Danish/Swedish multicenter study. The Scandinavian Isoprinosine Study Group]S Thorsen, C Pedersen, E Sandström, et al.
Journal of Internal Medicine|June 1, 1992
One-year follow-up on the safety and efficacy of isoprinosine for human immunodeficiency virus infection. Scandinavian Isoprinosine Study GroupS Thorsen, C Pedersen, E Sandström, et al.
The New England Journal of Medicine|June 21, 1990
The efficacy of inosine pranobex in preventing the acquired immunodeficiency syndrome in patients with human immunodeficiency virus infection. The Scandinavian Isoprinosine Study GroupC Pedersen, E Sandström, C S Petersen, et al.
Journal of Viral Hepatitis|April 14, 2010
Ribavirin plasma concentration is a predictor of sustained virological response in patients treated for chronic hepatitis C virus genotype 2/3 infectionC Pedersen, Å Alsiö, M Lagging, et al.
Journal of Viral Hepatitis|March 16, 2013
Dynamic tailoring of treatment durations improves efficiency of hepatitis C treatment with pegylated interferon and ribavirinM Lindh, B Arnholm, P Björkman, et al.
Alimentary Pharmacology & Therapeutics|January 29, 2015
Long-term follow-up of successful hepatitis C virus therapy: waning immune responses and disappearance of liver disease are consistent with cureM Hedenstierna, O Weiland, A Brass, et al.
Journal of Viral Hepatitis|May 27, 2010
Hepatitis C treatment response kinetics and impact of baseline predictorsM Lindh, B Arnholm, A Eilard, et al.
Journal of Viral Hepatitis|January 11, 2007
Impact of hepatic steatosis on viral kinetics and treatment outcome during antiviral treatment of chronic HCV infectionJ Westin, M Lagging, A P Dhillon, et al.
Pageof 17

Showing results (151-160 of 162) with videos related to

Sort By:
Pageof 17
Journal of Viral Hepatitis|June 23, 2011
IL28B polymorphisms determine early viral kinetics and treatment outcome in patients receiving peginterferon/ribavirin for chronic hepatitis C genotype 1M Lindh, M Lagging, B Arnholm, et al.
European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology|November 25, 2011
Early quantification of HCV core antigen may help to determine the duration of therapy for chronic genotype 2 or 3 HCV infectionA Alsiö, A Jannesson, N Langeland, et al.
Ugeskrift for Laeger|May 30, 1994
[Controlled, clinical trial of isoprinosine administration to HIV-infected patients. Results of a Danish/Swedish multicenter study. The Scandinavian Isoprinosine Study Group]S Thorsen, C Pedersen, E Sandström, et al.
Journal of Internal Medicine|June 1, 1992
One-year follow-up on the safety and efficacy of isoprinosine for human immunodeficiency virus infection. Scandinavian Isoprinosine Study GroupS Thorsen, C Pedersen, E Sandström, et al.
The New England Journal of Medicine|June 21, 1990
The efficacy of inosine pranobex in preventing the acquired immunodeficiency syndrome in patients with human immunodeficiency virus infection. The Scandinavian Isoprinosine Study GroupC Pedersen, E Sandström, C S Petersen, et al.
Journal of Viral Hepatitis|April 14, 2010
Ribavirin plasma concentration is a predictor of sustained virological response in patients treated for chronic hepatitis C virus genotype 2/3 infectionC Pedersen, Å Alsiö, M Lagging, et al.
Journal of Viral Hepatitis|March 16, 2013
Dynamic tailoring of treatment durations improves efficiency of hepatitis C treatment with pegylated interferon and ribavirinM Lindh, B Arnholm, P Björkman, et al.
Alimentary Pharmacology & Therapeutics|January 29, 2015
Long-term follow-up of successful hepatitis C virus therapy: waning immune responses and disappearance of liver disease are consistent with cureM Hedenstierna, O Weiland, A Brass, et al.
Journal of Viral Hepatitis|May 27, 2010
Hepatitis C treatment response kinetics and impact of baseline predictorsM Lindh, B Arnholm, A Eilard, et al.
Journal of Viral Hepatitis|January 11, 2007
Impact of hepatic steatosis on viral kinetics and treatment outcome during antiviral treatment of chronic HCV infectionJ Westin, M Lagging, A P Dhillon, et al.
Pageof 17